MESO

What one share of Mesoblast Limited holds

Biological Products, (No Diagnostic Substances)

Mesoblast Limited’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-06-30; the balance sheet is as of 2025-06-30.

Per-share figures
Sales$0.14
Profit−$0.85
Capex (buildings and equipment)$0.01
Free cash flow−$0.42
Cash and investments$1.26
Debt$0.95
Book value$4.67

Per share by fiscal year

YearSalesProfitCapexFree cashDividendsBook value
2016$1.17−$0.11———$14.50
2017$0.06−$1.93———$12.95
2018$0.37−$0.76———$11.31
2019$0.34−$1.82———$9.65
2020$0.61−$1.47———$9.41
2021$0.12−$1.63———$8.96
2022$0.15−$1.34———$7.64
2023$0.10−$1.05$0.00−$0.82—$6.16
2024$0.06−$0.89$0.00−$0.49—$4.21
2025$0.14−$0.85$0.01−$0.42—$4.67

Common questions about Mesoblast Limited

How much does one share of Mesoblast Limited earn?

Over its latest fiscal year, Mesoblast Limited lost $0.85 for each share on $0.14 of sales.

Does Mesoblast Limited pay a dividend?

Mesoblast Limited didn’t pay a dividend over its latest fiscal year, according to its SEC filings.

What is Mesoblast Limited’s book value per share?

Mesoblast Limited’s book value is $4.67 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2025.

How much cash and debt does each share of Mesoblast Limited have?

Each share of Mesoblast Limited has $1.26 of cash and investments and $0.95 of debt, as of June 30, 2025.

What is Mesoblast Limited’s free cash flow per share?

−$0.42 per share over its latest fiscal year. Free cash flow is the cash left over after spending on buildings and equipment.

Has Mesoblast Limited bought back shares?

Mesoblast Limited’s share count rose about 232% from 2016 to 2025. That dilution means each share owns a smaller slice of the company.

From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.